Associated Papers
Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers.
Gronkowska K et al.
Molecular Therapy. Oncology, 2024
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.
Dennis MJ et al.
Journal of Translational Medicine, 2024
39438862 (PubMed )
Supplement: 12967_2024_5761_MOESM2_ESM.xlsx › Full_Gene_List
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
37248814 (PubMed )
Supplement: supplement_1.xlsx › Supp._Table_5
Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
Luo M et al.
Molecular Medicine (cambridge, Mass.), 2023
High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.
Pillonel V et al.
Leukemia, 2018
29556019 (PubMed )
Supplement: 41375_2018_82_MOESM10_ESM.xlsx › .
Select a paper to view details